Skip to main content
NewslettersWatchlist

Viatris Inc(VTRS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low11.67
Day High12.82
Open:11.81
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
Barchart
How To Spot Good Value Stocks In A Sea Of Noise
Barchart
The Hidden Power Of Spinoffs: Why They Continue To Outperform
Motley Fool
3 Top Value Stocks to Buy Right Now
Barchart
Stocks Continue to Rebound in the Afternoon Trading Session
Barchart
Stocks Undercut by Mixed Corporate News
Barchart
Stocks Rally Sharply on Positive US Labor Market News
Motley Fool
Why Viatris Stock Is Jumping Today
Barchart
Stocks Rally as Economic Concerns Ease and Chip Stocks Climb
Barchart
Stocks Climb as US Weekly Jobless Claims Ease Economic Concerns
Motley Fool
3 Surprisingly Underrated Stocks to Buy Right Now
Barchart
Stocks Close Higher on Fed Rate Cut Optimism
Barchart
Stocks Rise on Fed Rate Cut Hopes
Barchart
Stocks Mixed as Weekly Jobless Claims Climb to an 8-1/2 Month High
Newswire.ca
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada
Barchart
Stocks Settle Higher on Strength in Megacap Tech Stocks
Motley Fool
Is Viatris a Great Dividend Stock or Just a Value Trap?
Motley Fool
2 Dirt Cheap Dividend Stocks to Buy and Hold
Barchart
Stocks Slip Before the Open as Key U.S. Inflation Data Looms
Barchart
Stocks Finish Lower Ahead of Thursday’s Core PCE Deflator Report
Barchart
Stocks Decline Ahead of Thursday’s Key Inflation Report
The Globe and Mail
17 U.S. stocks that may benefit from eventual easing in interest rates

Profile

Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.